Tejas Savant
Stock Analyst at Morgan Stanley
(2.18)
# 2,548
Out of 4,829 analysts
233
Total ratings
38.97%
Success rate
-6.07%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $79.58 | +25.66% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $62.11 | +4.65% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $58.42 | +11.26% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $7.09 | -1.27% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $9.22 | -2.33% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $8.38 | +19.33% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $12.70 | +18.16% | 17 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.04 | +145.10% | 13 | Mar 25, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $16 → $20 | $35.70 | -43.98% | 2 | Mar 18, 2025 | |
| NTRA Natera | Maintains: Overweight | $176 → $185 | $155.50 | +18.97% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $9.21 | +182.30% | 13 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $152.61 | +63.82% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $423.59 | +60.06% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $23.86 | -3.60% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $30.14 | -7.08% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $3.95 | +431.65% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.14 | +76.21% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.15 | +160.87% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.03 | +398.13% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $3.07 | +128.01% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.73 | +723.27% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.14 | +218.47% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.93 | -6.14% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $5.21 | -4.03% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.86 | +439.08% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $41.81 | +74.60% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $141.51 | +76.67% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.36 | +1,271.37% | 5 | May 12, 2022 |
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $79.58
Upside: +25.66%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $62.11
Upside: +4.65%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $58.42
Upside: +11.26%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.09
Upside: -1.27%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $9.22
Upside: -2.33%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $8.38
Upside: +19.33%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $12.70
Upside: +18.16%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.04
Upside: +145.10%
GRAIL
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $35.70
Upside: -43.98%
Natera
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $155.50
Upside: +18.97%
Feb 14, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $9.21
Upside: +182.30%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $152.61
Upside: +63.82%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $423.59
Upside: +60.06%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $23.86
Upside: -3.60%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $30.14
Upside: -7.08%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $3.95
Upside: +431.65%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.14
Upside: +76.21%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.15
Upside: +160.87%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.03
Upside: +398.13%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $3.07
Upside: +128.01%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.73
Upside: +723.27%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.14
Upside: +218.47%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.93
Upside: -6.14%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.21
Upside: -4.03%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.86
Upside: +439.08%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $41.81
Upside: +74.60%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $141.51
Upside: +76.67%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.36
Upside: +1,271.37%